

RECEIVED
CENTRAL FAX CENTER

OCT 14 2008

CANTOR COLBURN LLP
INTELLECTUAL PROPERTY ATTORNEYS
20 Church Street
22 Floor
Hartford, CT 06103-3207
Telephone: (860) 286-2929
FAX: (860) 286-0115

FACSIMILE TRANSMITTAL SHEET

DATE: October 14, 2008

TO: Assignment Division	RE: Notice of Recordation Correction
FAX NO.: 1-703-308-7124	
FROM: Andrea D. Sanders	
OUR REF: (NEU0027US2)	APPL NO.: 10/589,095
TITLE: IMIDAZO-PYRIDAZINES, TRIAZOLO-PYRIDAZINES AND RELATED BENZODIAZEPINE RECEPTOR LIGANDS	

TOTAL NUMBER OF PAGES SENT
(INCLUDING THIS COVER SHEET): 2

COMMENTS: Please correct the word Imadazo on the Assignment. It s/b IMIDAZO.

Thank you.

If there are any problems with this transmission, please call (860) 286-2929 and ask for Andrea D. Sanders at extension 1212.

NEU-0027

RECEIVED
CENTRAL FAX CENTER
OCT 14 2008

ASSIGNMENT

WHEREAS We, Yuelian Xu of 48 Highland Ave., East Haven, CT; Bingsong Han of 55 North Avenue, North Haven, CT; Linghong Xie of 136 Renee's Way, Guilford, CT; George D. Maynard of 27 Glenwood Road, Clinton, CT; (hereinafter "ASSIGNORS") have invented certain new and useful improvements in:

51b
ImIDAZO **IMADAZO-PYRIDAZINES, TRIAZOLO-PYRIDAZINES AND RELATED BENZODIAZEPINE RECEPTOR LIGANDS**

for which we have filed application for Letters Patent of the United States on August 9, 2006, U.S. Patent Application No. 10/589,095; which claims priority from U.S. Provisional Patent Application No. 60/544,057, filed February 12, 2004;

AND WHEREAS, NEUROGEN CORPORATION, a corporation organized and existing under the laws of the State of Delaware, having a place of business at 35 Northeast Industrial Road, Branford, CT 06405, is desirous of acquiring an interest in the United States and all foreign countries, in and to the said invention and Letters Patent to be obtained therefore;

NOW THEREFORE, TO ALL WHOM IT MAY CONCERN, be it known that, for good and sufficient consideration the, receipt of which is hereby acknowledged, We, the said ASSIGNORS; have sold, assigned, and transferred, and by these presents do sell, assign and transfer unto the said NEUROGEN CORPORATION, the entire right, title and interest in and to said invention in the United States and in all foreign countries, including priority rights, as fully set forth and described in said application; and We do hereby authorize and request the Commissioner of Patents to issue said Letters Patent on said application, and any and all Letters Patent that may be issued upon any and all revivals, refilings, continuations, continuations-in-part, divisions and reissues thereof, to the said NEUROGEN CORPORATION, an assignee of the entire right, title and interest in and to the same, for the sole use and behoof of NEUROGEN CORPORATION, its successors and assigns; and We do hereby agree that the said NEUROGEN CORPORATION, may apply for foreign Letters Patent on said invention and that We will execute all papers necessary in connection with the United States and foreign applications when called upon to do so by the said NEUROGEN CORPORATION, its successors or assigns, and that We will, at the cost and expense of the said NEUROGEN CORPORATION, fully assist and cooperate in all matters in connection with the United States and foreign applications and patents issuing thereon.

The undersigned declare that all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further that